Sequential emergence of ABL-kinase mutations with loss of unmutated BCR-ABL allele during targeted therapies of CML

被引：7
|
作者：
Sorel, Nathalie
Roy, Lydia
Martineau, Geraldine
Guilhot, Francois
Turhan, Ali G.
Chomel, Jean-Claude
机构：
[1] CHU Poitiers, Lab Hematol, F-86021 Poitiers, France
[2] CHU Poitiers, EA 3805, F-86021 Poitiers, France
来源：
BLOOD | 2006年 / 108卷 / 05期
关键词：
D O I：
10.1182/blood-2006-03-011668
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1782 / 1783
页数：2
相关论文
共 50 条
  • [31] Prevalence and dynamics of BCR-ABL independent gene mutations in chronic phase CML patients
    Ruppert, L.
    Rinke, J.
    Waldau, A.
    Hochhaus, A.
    Ernst, T.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 238 - 239
  • [32] Primary imatinib resistance in chronic myeloid leukemia patients in a developing country: BCR-ABL kinase domain mutations or BCR-ABL independent mechanisms?
    Yap, E.
    Tumian, N. R.
    Azma, R. Z.
    Sharifah, N. A.
    Salwati, S.
    Hamidah, N. H.
    Elias, M. H.
    Wong, C. L.
    MALAYSIAN JOURNAL OF PATHOLOGY, 2017, 39 (02) : 107 - 113
  • [33] Consecutive but not isolated BCR-ABL transcript level rises are predictive of BCR-ABL kinase mutations in chronic myeloid leukaemia patients treated by imatinib
    Clark, RE
    Knight, K
    Lucas, CM
    Wang, L
    EXPERIMENTAL HEMATOLOGY, 2005, 33 (07) : 52 - 52
  • [34] Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia
    H Pfeifer
    T Lange
    S Wystub
    B Wassmann
    J Maier
    A Binckebanck
    A Giagounidis
    M Stelljes
    M Schmalzing
    U Dührsen
    L Wunderle
    H Serve
    P Brück
    A Schmidt
    D Hoelzer
    O G Ottmann
    Leukemia, 2012, 26 : 1475 - 1481
  • [35] Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia
    Pfeifer, H.
    Lange, T.
    Wystub, S.
    Wassmann, B.
    Maier, J.
    Binckebanck, A.
    Giagounidis, A.
    Stelljes, M.
    Schmalzing, M.
    Duehrsen, U.
    Wunderle, L.
    Serve, H.
    Brueck, P.
    Schmidt, A.
    Hoelzer, D.
    Ottmann, O. G.
    LEUKEMIA, 2012, 26 (07) : 1475 - 1481
  • [36] Serial Analysis of BCR-ABL Kinase Domain Mutations Prior to and During Imatinib Treatment for Newly Diagnosed and Recurrent BCR-ABL Positive Acute Lymphoblastic Leukemia.
    Pfeifer, Heike
    Wystub, Sylvia
    Wassmann, Barbara
    Maier, Jaqueline
    Lange, Thoralf
    Hochhaus, Andreas
    Hoelzer, Dieter
    Ottmann, Oliver
    BLOOD, 2009, 114 (22) : 806 - 806
  • [37] The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib
    J S Khorashad
    M Anand
    D Marin
    S Saunders
    T Al-Jabary
    A Iqbal
    S Margerison
    J V Melo
    J M Goldman
    J F Apperley
    J Kaeda
    Leukemia, 2006, 20 : 658 - 663
  • [38] Prevalence and Dynamics of BCR-ABL Independent Gene Mutations in Chronic Phase CML Patients
    Ruppert, Lioba
    Rinke, Jenny
    Waldau, Anja
    Pfirrmann, Markus
    Hochhaus, Andreas
    Ernst, Thomas
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 106 - 106
  • [39] The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib
    Khorashad, JS
    Anand, M
    Marin, D
    Sauders, S
    Al-Jabary, T
    Iqbal, A
    Margerison, S
    Melo, JV
    Goldman, JM
    Apperley, JF
    Kaeda, J
    LEUKEMIA, 2006, 20 (04) : 658 - 663
  • [40] GENETIC APPROACHES TO DEFINING SIGNALING BY THE CML-ASSOCIATED TYROSINE KINASE BCR-ABL
    AFAR, DEH
    GOGA, A
    COHEN, L
    SAWYERS, CL
    MCLAUGHLIN, J
    MOHR, RN
    WITTE, ON
    COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, 1994, 59 : 589 - 594
12345